{"id":"W4409821748","doi":"10.1158/1538-7445.am2025-ct204","title":"Abstract CT204: Phase 1a/b study of runimotamab, a HER2 x CD3 T cell-engaging bispecific antibody, administered as a single agent and in combination with trastuzumab in patients with HER2-expressing breast cancer (BC)","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Trastuzumab; Bispecific antibody; Medicine; Antibody; Internal medicine; Oncology; Cancer; Monoclonal antibody; Immunology; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000800474,0.001651104,0.001218157,0.0005334929,0.0004713275,0.0009107318,0.0009917647,0.001270802,0.004997592],"category_scores_gemma":[0.0005871886,0.000538388,0.0007952721,0.0004062649,0.0007598993,0.0005943202,0.0003051281,0.003226056,0.001168806],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001102759,"about_ca_system_score_gemma":0.001825556,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001813217,"about_ca_topic_score_gemma":0.003560656,"domain_scores_codex":[0.9997286,0.0001106706,0.00001092514,0.00004806164,0.00003119557,0.00007046563],"domain_scores_gemma":[0.9996002,0.0000498835,0.00006239471,0.00002687587,0.00003403765,0.0002265467],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5005181,0.1123858,0.008063454,0.001219591,0.00107708,0.0009387707,0.0004639558,0.005314406,0.2380849,0.0005582396,0.01122687,0.1201488],"study_design_scores_gemma":[0.3028469,0.6600242,0.01165822,0.00004839341,0.0003137918,0.0006731224,0.00005186104,0.001412421,0.01800491,0.0001848814,0.004745561,0.00003578919],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902744,0.001413604,0.0005189973,0.0004369782,0.00008127383,0.002498815,0.00166846,0.0001672466,0.002940295],"genre_scores_gemma":[0.9849817,0.001186594,0.001567028,0.0007582559,0.000130577,0.002280513,0.003984673,0.00004493955,0.005065792],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004997592,"threshold_uncertainty_score":0.01671857,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05858182442711424,"score_gpt":0.4142998698667913,"score_spread":0.3557180454396771,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}